Observational studyNature medicine2025
Clinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis.
Observational study in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Recent advances in screening, diagnosis, prognosis and personalized treatment of sepsis.European journal of microbiology & immunology · 2026Review
- Real‑world clinical evaluation of the Inflammatix TriVerity test for sepsis at the emergency department-an Acutelines study: comment.Internal and emergency medicine · 2026Article
- Rapid Diagnostics for Distinguishing Bacterial and Viral Infections: A Review of Technologies, Clinical Utility, and Stewardship Implications.Biosensors · 2026Review
- Early Identification of a Cytokine-Low Immune Phenotype in Suspected Sepsis Using a Point-of-Care Whole-Blood TNF-α Release Assay.Medical sciences (Basel, Switzerland) · 2026Article
- Real-world clinical evaluation of the Inflammatix TriVerity test for sepsis at the emergency department: an Acutelines study.Internal and emergency medicine · 2026Article
- The molecular ICU: a primer on omics, informatics and the future of precision critical care.Critical care (London, England) · 2026Review
- Aligning neonatal sepsis triage diagnostics with WHO target product profiles in low- and middle-income countries.BMJ global health · 2026Review
- Artificial Intelligence in Infectious Disease Care: Selected Applications in Tuberculosis, Sepsis, and Antimicrobial Stewardship.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Incorporating WGCNA and Machine Learning to Identify ADAP2 as a Critical Efferocytosis-Related Gene in Sepsis.Pathogens (Basel, Switzerland) · 2026Article
- Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026.Intensive care medicine · 2026Article
- Integrating Precision Sepsis Risk Stratification Into Systems-Based Antimicrobial Stewardship.Open forum infectious diseases · 2026Article
- Artificial intelligence for sepsis management in the emergency department.BMC infectious diseases · 2026Review
- Alveolar Immune Profiling Identifies Distinct Subphenotypes of Acute Respiratory Failure.medRxiv : the preprint server for health sciences · 2026Article
- Hyper-inflammation and immunosuppression: redefining sepsis therapy using modern approaches.Frontiers in pharmacology · 2026Review
- Point-of-care LPS-induced TNF-α release testing for early sepsis risk stratification in the emergency department.Frontiers in immunology · 2026Observational
- Blood Host-Response mRNA Assays in Adult Acute Care: Diagnostic Performance, Translational Evidence, and the Clinical Implementation Gap.Infection and drug resistance · 2026Review
- Systems biology approaches to unravelling neonatal sepsis and potential for precision diagnostics and therapeutics.Frontiers in pharmacology · 2026Review
- Unlocking host response signatures in sepsis and critical illnesses.Nature medicine · 2025Article
- Research Progress on Sepsis Diagnosis and Monitoring Based on Omics Technologies: A Review.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
Abstract
Lack of reliable diagnostics for the presence, type and severity of infection in patients presenting to emergency departments with non-specific symptoms poses considerable challenges. We developed TriVerity, which uses isothermal amplification of 29 mRNAs and machine learning algorithms on the Myrna instrument to determine likelihoods of bacterial infection, viral infection and need for critical care interventions within 7 days. To validate TriVerity, the SEPSIS-SHIELD study enrolled 1,222 patients with clinically adjudicated infection status and need for critical care intervention within 7 days as endpoints. The TriVerity Bacterial and Viral scores had higher accuracy than C-reactive protein, procalcitonin or white blood cell count for the diagnosis of bacterial infection with area under the receiver operating characteristic (AUROC) of 0.83, and viral infection (AUROC = 0.91). The TriVerity Severity score had an AUROC of 0.78 for predicting illness severity and allowed reclassification of risk for critical care interventions compared to clinical assessment (quick Sequential Organ Failure Assessment) alone. Each of the three scores had rule-in specificity >92% and rule-out sensitivity >95%. Comparison of antibiotics administration at presentation with post-follow-up adjudication found that TriVerity could potentially reduce false positives and false negatives for inappropriate antibiotics use by 60-70%. Further clinical testing in an interventional setting is needed to prove actionability and clinical benefit of TriVerity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.